Market cap
$92 Mln
Revenue (TTM)
$4 Mln
P/E Ratio
--
P/B Ratio
7.9
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | 43.88 | 1,114.77 | 178.08 | -18.05 | 199.30 |
| EBIT | -- | -- | -157.26 | 6.64 | -43.86 |
| Net Profit | 80.09 | 26.93 | -45.72 | 5.63 | -173.44 |
| EPS | -- | -- | -- | -- | -- |
| Book Value | -- | -- | -- | -- | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-24 | Dec-23 |
| EBIT-Margin
| -2,268.52 | -2,006.20 | -1,349.41 | -3,220.57 | -1,650.23 |
| Net Margin
| -17,485.71 | 136,461.69 | -1,514.57 | -- | -- |
| Return on equity
| -383.75 | -274.84 | -584.12 | -910.86 | -92.78 |
| Return on Capital
| -276.67 | -203.87 | -- | -611.12 | -83.81 |
| Return on Assets
| -66.21 | -64.22 | -77.95 | -110.32 | -31.75 |
| Debt to Equity (x)
| -- | -- | 0.00 | -0.30 | 0.11 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
OncoCyte Corp (OCX)
|
--
|
-611.12
|
-83.81
|
-135.09
|
-113.44
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
-584.12
Lower than Peers by 543.83
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
OncoCyte Corp (OCX)
|
-584.12
|
-910.86
|
-92.78
|
-147.60
|
-129.88
|
|
Peer Median
|
-40.29
|
--
|
--
|
--
|
--
|
ROA
-77.95
Lower than Peers by 47.11
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
OncoCyte Corp (OCX)
|
-77.95
|
-110.32
|
-31.75
|
-56.57
|
-59.63
|
|
Peer Median
|
-30.84
|
--
|
--
|
--
|
--
|
EBIT Margin
-1,349.41
Lower than Peers by 1,267.20
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
OncoCyte Corp (OCX)
|
-1,349.41
|
-3,220.57
|
-1,650.23
|
-1,934.76
|
-681.53
|
|
Peer Median
|
-82.21
|
--
|
--
|
--
|
--
|
Net Margin
-1,514.57
Lower than Peers by 1,424.69
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
OncoCyte Corp (OCX)
|
-1,514.57
|
-3,225.04
|
-1,848.37
|
-17,485.71
|
-729.20
|
|
Peer Median
|
-89.88
|
--
|
--
|
--
|
--
|
Cash Profit Margin
0.00
Lower than Peers by 0.00
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
OncoCyte Corp (OCX)
|
0.00
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.00
|
--
|
--
|
--
|
--
|
Revenue Growth
178.08
Higher than Peers by 124.04
Year on year growth in net sales
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
OncoCyte Corp (OCX)
|
178.08
|
0.25
|
0.57
|
-0.88
|
5.35
|
|
Peer Median
|
54.03
|
--
|
--
|
--
|
--
|
EBIT Growth
-157.26
Lower than Peers by 156.30
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
OncoCyte Corp (OCX)
|
-157.26
|
-144.24
|
-33.82
|
64.80
|
-70.24
|
|
Peer Median
|
-0.95
|
--
|
--
|
--
|
--
|
Net Profit Growth
-45.72
Lower than Peers by 38.54
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
OncoCyte Corp (OCX)
|
-45.72
|
-118.36
|
62.17
|
-14.58
|
-114.14
|
|
Peer Median
|
-7.19
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
OncoCyte Corp (OCX)
|
--
|
-0.30
|
0.11
|
0.10
|
0.09
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
0.14
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
OncoCyte Corp (OCX)
|
0.14
|
-0.11
|
0.03
|
0.05
|
0.05
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
3.75
Lower than Peers by 2.06
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
OncoCyte Corp (OCX)
|
3.75
|
1.62
|
1.49
|
2.11
|
2.77
|
|
Peer Median
|
5.80
|
--
|
--
|
--
|
--
|
Quick Ratio
3.70
Lower than Peers by 2.00
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
OncoCyte Corp (OCX)
|
3.70
|
1.56
|
1.49
|
1.93
|
2.75
|
|
Peer Median
|
5.69
|
--
|
--
|
--
|
--
|
Interest Coverage
-592.93
Lower than Peers by 590.84
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
OncoCyte Corp (OCX)
|
-592.93
|
-721.18
|
-476.98
|
-223.31
|
-251.97
|
|
Peer Median
|
-2.09
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
92.12
Higher than Peers by 73.14
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
OncoCyte Corp (OCX)
|
92.12
|
85.75
|
32.20
|
210.02
|
18.60
|
|
Peer Median
|
18.97
|
--
|
--
|
--
|
--
|
Asset Turnover
0.05
Lower than Peers by 0.01
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
OncoCyte Corp (OCX)
|
0.05
|
0.03
|
0.02
|
0.01
|
0.07
|
|
Peer Median
|
0.07
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
OncoCyte Corp (OCX)
|
--
|
203.60
|
303.28
|
657.49
|
38.76
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
OncoCyte Corp (OCX)
|
--
|
65.62
|
355.36
|
453.76
|
7.36
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
OncoCyte Corp (OCX)
|
--
|
517.30
|
369.61
|
573.14
|
54.31
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
OncoCyte Corp (OCX)
|
--
|
-248.08
|
289.04
|
538.11
|
-8.19
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Book Value
7.92
Higher than Peers by 2.57
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
OncoCyte Corp (OCX)
|
7.92
|
--
|
--
|
--
|
--
|
|
Peer Median
|
5.35
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
OncoCyte Corp (OCX)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
-1.25
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
OncoCyte Corp (OCX)
|
-1.25
|
0.08
|
0.28
|
1.27
|
0.64
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
92
Lower than Peers by 56
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
OncoCyte Corp (OCX)
|
92
|
--
|
--
|
--
|
--
|
|
Peer Median
|
147
|
--
|
--
|
--
|
--
|